Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    J Virol. 2012 Apr;86(8):4688-92. doi: 10.1128/JVI.07163-11. Epub 2012 Feb 1.

    Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

    Source

    Duke Human Vaccine Institute, Durham, North Carolina, USA. mattia.bonsignori@duke.edu

    Abstract

    Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.

    PMID:
    22301150
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3318651
    Free PMC Article

    Images from this publication.See all images (3)Free text

    Fig 1
    Fig 3
    Fig 2

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk